Oppenheimer Maintains Outperform on CalciMedica, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell maintains an Outperform rating on CalciMedica (NASDAQ:CALC) with a $14 price target, indicating a positive outlook on the company's stock.
April 01, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Leland Gershell maintains an Outperform rating on CalciMedica with a $14 price target, suggesting a strong growth potential.
The reaffirmation of the Outperform rating and the maintenance of a $14 price target by a reputable analyst suggests a strong conviction in the company's future performance. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100